NasdaqGS:KRYSBiotechs
Krystal Biotech’s RMAT Win Puts KB707 At Core Of Oncology Story
Krystal Biotech (NasdaqGS:KRYS) received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for KB707 in advanced non small cell lung cancer.
The designation focuses on KB707, a redosable immunotherapy candidate being studied in an ongoing clinical trial.
RMAT status provides access to more frequent FDA interactions and certain expedited programs, including the potential for rolling review.
For you as an investor, this RMAT milestone highlights how Krystal Biotech is extending...